Abstract Chimeric antigen receptor-T cell(CAR-T) is a kind of genetically engineered T cells that can express tumor antigen-specific receptors on its surface, and the modified T cells can be used for cancer therapy through targeting malignant tumor cells with its specific receptor and killing tumor cells with its cytotoxicity. CAR-T has been successfully applied to treat various hematological malignancies, such as ALL, CLL, NHL and MM. It is a feasible treatment for relapsed and refractory multiple myeloma (RRMM). The achievements of CAR-T in clinical trials have been widely reported, which is expected to be a therapy to prolong patients survival. In this review, the clinical application of CAR-T in the treatment of RRMM from the following aspects：different types of CAR-T and its curative efficacy, adverse effects, opportunities and challenges are summarized beriefly.
题目: 嵌合抗原受体T细胞治疗复发难治性多发性骨髓瘤的最新研究进展.
摘要: 嵌合抗原受体T细胞（chimeric antigen receptor-T cells，CAR-T）是用基因工程的方法进行人工改造的T细胞。CAR-T细胞可以表达肿瘤抗原特异性受体，该受体能特异性地识别并结合恶性肿瘤细胞，CAR-T细胞被激活时，可利用细胞毒性作用杀伤肿瘤细胞，该方法已在临床上成功地运用于治疗多种血液系统恶性肿瘤，如ALL、CLL、NHL、MM等。CAR-T细胞常被用于治疗复发难治性多发性骨髓瘤（RRMM），已有许多研究机构报道了其在临床试验中取得的成果，该方法提高了MM患者的治疗效果并延长生存时间。本文从多种CAR-T的疗效、不良反应、机遇与挑战等方面进行综述.